| Symbol | RIGL |
|---|---|
| Name | RIGEL PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080 |
| Telephone | 650-624-1100 |
| Fax | — |
| — | |
| Website | https://www.rigel.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001034842 |
| Description | Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Companys marketed products and pipeline of potential products, visit https://www.rigel.com/. Additional info from NASDAQ: |
2026-07-07 12:05
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read more
2026-07-01 12:05
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Read more
2026-07-01 12:05
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Read more
2026-06-24 20:04
Ali-Jackson Kamil 🔴 sold 2.5K shares of RIGEL PHARMACEUTICALS INC (RIGL) at $35.00 Transaction Date: Jun 22, 2026 | Filing ID: 003076
Read more
2026-06-22 20:12
Furey Raymond J. 🟢 acquired 7.4K shares (1 derivative) of RIGEL PHARMACEUTICALS INC (RIGL) at $22.49 Transaction Date: Jun 17, 2026 | Filing ID: 003039
Read more
2026-06-22 20:11
Rojkjaer Lisa 🟢 acquired 16.8K shares (2 derivative) of RIGEL PHARMACEUTICALS INC (RIGL) at $22.49 Transaction Date: Jun 17, 2026 | Filing ID: 003040
Read more
2026-06-22 20:11
Schorno Dean L 🟢 acquired 7.4K shares (1 derivative) of RIGEL PHARMACEUTICALS INC (RIGL) at $22.49 Transaction Date: Jun 17, 2026 | Filing ID: 003036
Read more
2026-06-22 20:11
Santos David A 🟢 acquired 7.4K shares (1 derivative) of RIGEL PHARMACEUTICALS INC (RIGL) at $22.49 Transaction Date: Jun 17, 2026 | Filing ID: 003037
Read more
2026-06-22 19:12
📋 Ali-Jackson Kamil (Director) plans to sell 2K shares of RIGEL PHARMACEUTICALS INC (at $35.00 each, total $88K) Filed: Jun 22, 2026 | ID: 004799
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03363334 | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsin… | — | Immune Thrombocytopenic Purpura | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06564207 | Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospita… | Phase2 | Acute Respiratory Distress Syndrome | Not_Yet_Recruiting | 2026-08-30 | 2027-10-31 | ClinicalTrials.gov |
| NCT07471841 | Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received… | Phase2 | IDH1 Mutation | Recruiting | 2026-07-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT06782542 | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute… | Phase2 | Acute Myeloid Leukemia | Recruiting | 2026-03-31 | 2029-03-31 | ClinicalTrials.gov |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | Phase4 | AML (Acute Myeloid Leukemia) | Recruiting | 2026-02-23 | 2027-06-30 | ClinicalTrials.gov |
| NCT07130695 | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Conso… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2026-02-02 | 2030-10-31 | ClinicalTrials.gov |
| NCT07032727 | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-m… | Phase2 | Targeted Therapy | Recruiting | 2025-09-12 | 2029-06-01 | ClinicalTrials.gov |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | Phase2 | High Grade Glioma | Recruiting | 2025-02-01 | 2035-06-01 | ClinicalTrials.gov |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Age… | Phase2 | Chronic Myelomonocytic Leukemia | Withdrawn | 2025-01-28 | 2026-06-11 | ClinicalTrials.gov |
| NCT06566742 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cy… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2024-12-10 | 2029-08-31 | ClinicalTrials.gov |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pa… | Phase1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | 2024-12-05 | 2028-12-01 | ClinicalTrials.gov |
| NCT06445959 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted … | Phase1 | Mutant IDH1 Inhibitor Olutasidenib | Recruiting | 2024-08-29 | 2029-06-30 | ClinicalTrials.gov |
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase1 | Low Risk Myelodysplastic Syndromes | Recruiting | 2022-09-12 | 2026-12-01 | ClinicalTrials.gov |
| NCT05040698 | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting … | Phase2 | Hidradenitis Suppurativa | Completed | 2021-10-01 | 2023-01-27 | ClinicalTrials.gov |
| NCT04904276 | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients Wi… | — | ITP | Terminated | 2021-05-18 | 2022-11-17 | ClinicalTrials.gov |
| NCT04543279 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment… | Phase2 | Myelofibrosis | Terminated | 2021-05-03 | 2022-07-30 | ClinicalTrials.gov |
| NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Eva… | Phase3 | Covid19 | Completed | 2021-03-25 | 2022-09-05 | ClinicalTrials.gov |
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment … | Phase3 | Warm Antibody Autoimmune Hemolytic Anemia | Enrolling_By_Invitation | 2019-10-30 | 2024-04-01 | ClinicalTrials.gov |
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of… | Phase3 | Warm Antibody Autoimmune Hemolytic Anemia | Completed | 2019-04-24 | 2022-04-11 | ClinicalTrials.gov |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Phase1 | Ovarian Cancer | Completed | 2018-04-03 | 2023-04-03 | ClinicalTrials.gov |
| NCT02612558 | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoim… | Phase2 | Warm Antibody Autoimmune Hemolytic Anemia | Completed | 2016-07-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02433236 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | Phase2 | IGA Nephropathy | Withdrawn | 2015-09-01 | — | ClinicalTrials.gov |
| NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chro… | Phase3 | Immune Thrombocytopenic Purpura | Completed | 2015-01-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02112838 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephrop… | Phase2 | IGA Nephropathy | Completed | 2014-10-01 | 2018-11-12 | ClinicalTrials.gov |
| NCT02077192 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thromboc… | Phase3 | Immune Thrombocytopenic Purpura | Completed | 2014-10-01 | 2020-06-02 | ClinicalTrials.gov |
| NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic I… | Phase3 | Immune Thrombocytopenic Purpura | Completed | 2014-07-14 | 2016-04-21 | ClinicalTrials.gov |
| NCT02040623 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graf… | Phase2 | Chronic Graft-versus-host Disease | Completed | 2014-03-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01900249 | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients W… | Phase2 | Keratoconjunctivitis Sicca | Completed | 2013-07-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01733992 | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patie… | Phase1 | Keratoconjunctivitis Sicca | Completed | 2012-11-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01597050 | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosu… | Phase2 | Lupus Erythematosus, Discoid | Completed | 2012-08-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01591044 | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderat… | Phase2 | Asthma | Completed | 2012-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymp… | Phase2 | T Cell Lymphoma | Completed | 2009-03-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00752999 | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythemato… | Phase2 | Systemic Lupus Erythematosus | Withdrawn | 2008-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00665626 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Tas… | Phase2 | Rheumatoid Arthritis | Completed | 2008-05-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00665925 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Completed | 2008-05-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00446095 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | Phase1 | Lymphoma | Completed | 2007-04-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00706342 | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refract… | Phase2 | Purpura, Thrombocytopenic, Idiopathic | Completed | 2007-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00326339 | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) | Phase2 | Rheumatoid Arthritis | Completed | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00115089 | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seaso… | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2005-07-01 | 2005-09-01 | ClinicalTrials.gov |
Total clinical trials: 39
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Olutasidenib | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT06566742 |
| Olutasidenib | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT06566742 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Azacitidine (AZA) | Other | Phase PHASE2 | IDH1 Mutation | RECRUITING | NCT07471841 |
| Olutasidenib | Other | Phase PHASE2 | IDH1 Mutation | RECRUITING | NCT07471841 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Olutasidenib + TMZ | Other | Phase PHASE2 | High Grade Glioma | RECRUITING | NCT06161974 |
| CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | Other | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Olutasidenib | Other | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Azacitidine (AZA) | Other | Phase PHASE2 | IDH1 Mutation | NOT_YET_RECRUITING | NCT07471841 |
| Olutasidenib | Other | Phase PHASE2 | IDH1 Mutation | NOT_YET_RECRUITING | NCT07471841 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | WITHDRAWN | NCT06597734 |
| Placebo | Other | Phase PHASE1 | Keratoconjunctivitis Sicca | COMPLETED | NCT01733992 |
| R348 Ophthalmic Solution, 1.0% | Other | Phase PHASE1 | Keratoconjunctivitis Sicca | COMPLETED | NCT01733992 |
| R348 Ophthalmic Solution, 0.5% | Other | Phase PHASE1 | Keratoconjunctivitis Sicca | COMPLETED | NCT01733992 |
| R348 Ophthalmic Solution, 0.2% | Other | Phase PHASE1 | Keratoconjunctivitis Sicca | COMPLETED | NCT01733992 |
| Fostamatinib Disodium tablet 150 mg | Other | Phase PHASE2 | IGA Nephropathy | WITHDRAWN | NCT02433236 |
| Fostamatinib Disodium tablet 100 mg | Other | Phase PHASE2 | IGA Nephropathy | WITHDRAWN | NCT02433236 |
| Placebo | Other | Phase PHASE2 | Lupus Erythematosus, Discoid | COMPLETED | NCT01597050 |
| R932333 | Other | Phase PHASE2 | Lupus Erythematosus, Discoid | COMPLETED | NCT01597050 |
| R940343 2mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01591044 |
| R940343 1mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01591044 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01591044 |
| Placebo | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01900249 |
| R348 Ophthalmic Solution, 0.5% | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01900249 |
| R348 Ophthalmic Solution, 0.2% | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01900249 |
| Placebo Ophthalmic Solution | Other | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| R348 Ophthalmic Solution, 0.5% | Other | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| R348 Ophthalmic Solution, 0.2% | Other | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| Fostamatinib disodium 150 mg | Other | Preclinical | Immune Thrombocytopenic Purpura | NO_LONGER_AVAILABLE | NCT03363334 |
| Fostamatinib disodium 100 mg | Other | Preclinical | Immune Thrombocytopenic Purpura | NO_LONGER_AVAILABLE | NCT03363334 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02076412 |
| Fostamatinib Disodium | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02076412 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02076399 |
| Fostamatinib disodium | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02076399 |
| Placebo | Other | Phase PHASE2 | IGA Nephropathy | COMPLETED | NCT02112838 |
| Fostamatinib 100 mg | Other | Phase PHASE2 | IGA Nephropathy | COMPLETED | NCT02112838 |
| Fostamatinib 150 mg | Other | Phase PHASE2 | IGA Nephropathy | COMPLETED | NCT02112838 |
| Fostamatinib 150 mg bid | Other | Phase PHASE2 | Warm Antibody Autoimmune Hemolytic Anemia | COMPLETED | NCT02612558 |
| Fostamatinib disodium | Other | Phase PHASE3 | Warm Antibody Autoimmune Hemolytic Anemia | ENROLLING_BY_INVITATION | NCT04138927 |
| Fostamatinib | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05040698 |
| Placebo | Other | Phase PHASE3 | Warm Antibody Autoimmune Hemolytic Anemia | COMPLETED | NCT03764618 |
| Fostamatinib disodium | Other | Phase PHASE3 | Warm Antibody Autoimmune Hemolytic Anemia | COMPLETED | NCT03764618 |
| Placebo | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04629703 |
| Fostamatinib | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04629703 |
| Fostamatinib Disodium | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02077192 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | TERMINATED | NCT04543279 |
| Fostamatinib | Other | Phase PHASE2 | Myelofibrosis | TERMINATED | NCT04543279 |
| Fostamatinib | Other | Preclinical | ITP | TERMINATED | NCT04904276 |
| Fostamatinib 200 mg bid and Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Fostamatinib 150 mg bid and Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Fostamatinib 100 mg bid and Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Olutasidenib + TMZ | Other | Phase PHASE2 | High Grade Glioma | RECRUITING | NCT06161974 |
| R906289 Monosodium (R289 Na) | Other | Phase PHASE1 | Low Risk Myelodysplastic Syndromes | RECRUITING | NCT05308264 |
| Olutasidenib Investigational Agent Administration | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07130695 |
| Olutasidenib | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT06566742 |
| CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | Other | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Olutasidenib | Other | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) | Drug | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT06639724 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine/cedazuridine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Olutasidenib | Other | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Cytarabine | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Ruxolitinib | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Gilteritinib | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Venetoclax | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Cladribine (CLAD) | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Olutasidenib | Other | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Olutasidenib | Other | Phase PHASE2 | Chronic Myelomonocytic Leukemia | RECRUITING | NCT06597734 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Venetoclax | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Olutasidenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Venetoclax | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Olutasidenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Venetoclax | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Olutasidenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Venetoclax | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Olutasidenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| ORE1001 | DRUG | Phase PHASE1 | Mild to Moderate Ulcerative Colitis | UNKNOWN | NCT01039597 |
| JNJ-32729463 (Open-Label) | DRUG | Phase PHASE2 | Community-Acquired Bacterial Pneumonia (CABP) | TERMINATED | NCT01198626 |
| moxifloxacin | DRUG | Phase PHASE2 | Community-Acquired Bacterial Pneumonia (CABP) | TERMINATED | NCT01198626 |
| RP-G28 or placebo | DRUG | Phase PHASE2 | Lactose Intolerance | COMPLETED | NCT01113619 |
| linezolid placebo | DRUG | Phase PHASE2 | Complicated Skin and Skin Structure Infections | COMPLETED | NCT01128530 |
| JNJ-32729463 placebo | DRUG | Phase PHASE2 | Complicated Skin and Skin Structure Infections | COMPLETED | NCT01128530 |
| linezolid | DRUG | Phase PHASE2 | Complicated Skin and Skin Structure Infections | COMPLETED | NCT01128530 |
| JNJ-32729463 | DRUG | Phase PHASE2 | Community-Acquired Bacterial Pneumonia (CABP) | TERMINATED | NCT01198626 |
| Atorvastatin | DRUG | Phase PHASE2 | Myalgia | COMPLETED | NCT01279590 |
| PPD10558 | DRUG | Phase PHASE2 | Myalgia | COMPLETED | NCT01279590 |
| [Tc-99m]-RPI-T-087 Injection | DRUG | Phase PHASE1 | Healthy | UNKNOWN | NCT03503825 |
| Placebos | DRUG | Phase PHASE3 | Lactose Intolerance | COMPLETED | NCT03597516 |
| RP-G28 | DRUG | Phase PHASE2 | Lactose Intolerance | COMPLETED | NCT02673749 |
| Eluxadoline | DRUG | Phase PHASE3 | Irritable Bowel Syndrome | COMPLETED | NCT01553747 |
| Vehicle ophthalmic solution | OTHER | Phase PHASE3 | Blepharoptosis | COMPLETED | NCT03565887 |
| RVL-1201 Vehicle Placebo | DRUG | Phase PHASE1 | Blepharoptosis | COMPLETED | NCT01848041 |
| RVL-1201 | DRUG | Phase PHASE3 | Blepharoptosis | COMPLETED | NCT03565887 |
| baclofen | DRUG | Phase PHASE3 | Spasticity | COMPLETED | NCT01743651 |
| arbaclofen | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01844232 |
| Placebo for arbaclofen ER tablets | DRUG | Phase PHASE3 | Multiple Sclerosis | WITHDRAWN | NCT02869425 |
| arbaclofen ER Tablets | DRUG | Phase PHASE3 | Multiple Sclerosis | WITHDRAWN | NCT02869425 |
| Arbaclofen | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT03290131 |
| RVP-001 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05413668 |
| CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | DRUG | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Azacitidine (AZA) | DRUG | Phase PHASE2 | IDH1 Mutation | NOT_YET_RECRUITING | NCT07471841 |
| Olutasidenib Investigational Agent Administration | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07130695 |
| Cytarabine | DRUG | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Gilteritinib | DRUG | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Cladribine (CLAD) | DRUG | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Azacitidine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06782542 |
| Decitabine/cedazuridine | DRUG | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Decitabine | DRUG | Phase PHASE1 | Mutant IDH1 Inhibitor Olutasidenib | RECRUITING | NCT06445959 |
| Venetoclax | DRUG | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Olutasidenib | DRUG | Phase PHASE4 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT07486713 |
| Olutasidenib + TMZ | DRUG | Phase PHASE2 | High Grade Glioma | RECRUITING | NCT06161974 |
| R906289 Monosodium (R289 Na) | DRUG | Phase PHASE1 | Low Risk Myelodysplastic Syndromes | RECRUITING | NCT05308264 |
| Ruxolitinib | DRUG | Phase PHASE2 | Targeted Therapy | RECRUITING | NCT07032727 |
| Fostamatinib | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome | NOT_YET_RECRUITING | NCT06564207 |
| Fostamatinib disodium 150 mg | DRUG | Preclinical | Immune Thrombocytopenic Purpura | NO_LONGER_AVAILABLE | NCT03363334 |
| Fostamatinib disodium 100 mg | DRUG | Preclinical | Immune Thrombocytopenic Purpura | NO_LONGER_AVAILABLE | NCT03363334 |
| Fostamatinib 200 mg bid and Paclitaxel | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Fostamatinib 150 mg bid and Paclitaxel | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Fostamatinib 100 mg bid and Paclitaxel | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03246074 |
| Fostamatinib 150 mg bid | DRUG | Phase PHASE2 | Warm Antibody Autoimmune Hemolytic Anemia | COMPLETED | NCT02612558 |
| Fostamatinib Disodium tablet 150 mg | DRUG | Phase PHASE2 | IGA Nephropathy | WITHDRAWN | NCT02433236 |
| Fostamatinib Disodium tablet 100 mg | DRUG | Phase PHASE2 | IGA Nephropathy | WITHDRAWN | NCT02433236 |
| Fostamatinib 100 mg | DRUG | Phase PHASE2 | IGA Nephropathy | COMPLETED | NCT02112838 |
| Fostamatinib 150 mg | DRUG | Phase PHASE2 | IGA Nephropathy | COMPLETED | NCT02112838 |
| Fostamatinib disodium | DRUG | Phase PHASE3 | Warm Antibody Autoimmune Hemolytic Anemia | ENROLLING_BY_INVITATION | NCT04138927 |
| Placebo Ophthalmic Solution | OTHER | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| R348 Ophthalmic Solution, 1.0% | DRUG | Phase PHASE1 | Keratoconjunctivitis Sicca | COMPLETED | NCT01733992 |
| R348 Ophthalmic Solution, 0.5% | DRUG | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| R348 Ophthalmic Solution, 0.2% | DRUG | Phase PHASE2 | Chronic Graft-versus-host Disease | COMPLETED | NCT02040623 |
| R932333 | DRUG | Phase PHASE2 | Lupus Erythematosus, Discoid | COMPLETED | NCT01597050 |
| R940343 2mg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01591044 |
| R940343 1mg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01591044 |
| Fostamatinib Disodium | DRUG | Phase PHASE3 | Immune Thrombocytopenic Purpura | COMPLETED | NCT02077192 |
| Fostamatinib Disodium (R935788) | DRUG | Phase PHASE2 | Systemic Lupus Erythematosus | WITHDRAWN | NCT00752999 |
| Fostamatinib Disodium / R935788 | DRUG | Phase PHASE2 | Purpura, Thrombocytopenic, Idiopathic | COMPLETED | NCT00706342 |
| Fostamatinib disodium (R935788) | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00665925 |
| fostamatinib | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00446095 |
| Placebo | DRUG | Phase PHASE1 | Mild to Moderate Ulcerative Colitis | UNKNOWN | NCT01039597 |
| R788 | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00326339 |
| Beclomethasone dipropionate | DRUG | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00115089 |
| R926112 | DRUG | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00115089 |
Total products: 213